1.
Stereotyped B-cell responses are linked to IgG constant region polymorphisms in multiple sclerosis. Lindeman I, Polak J, Qiao SW, Holmøy T, Høglund RA, Vartdal F, Berg-Hansen P, Sollid LM, Lossius A.
Eur J Immunol. 2022 Jan 29. doi: 10.1002/eji.202149576. Online ahead of print.
PMID: 35094395
2.
Telemedicine as a strategic intervention for cognitive rehabilitation in MS patients during COVID-19. Ghadiri F, Naser Moghadasi A, Sahraian MA.
Acta Neurol Belg. 2022 Jan 30. doi: 10.1007/s13760-022-01875-7. Online ahead of print.
PMID: 35094365 Review.
3.
MIND Diet Adherence Might be Associated with a Reduced Odds of Multiple Sclerosis: Results from a Case-Control Study. Noormohammadi M, Ghorbani Z, Naser Moghadasi A, Saeedirad Z, Shahemi S, Ghanaatgar M, Rezaeimanesh N, Hekmatdoost A, Ghaemi A, Razeghi Jahromi S.
Neurol Ther. 2022 Jan 29. doi: 10.1007/s40120-022-00325-z. Online ahead of print.
PMID: 35094301
4.
Validity and reliability of the Tampa Kinesiophobia-Fatigue Scale in patients with multiple sclerosis. Kese B, Salcı Y, Yılmaz ÖT.
Ir J Med Sci. 2022 Jan 30. doi: 10.1007/s11845-021-02902-x. Online ahead of print.
PMID: 35094232
5.
Mortality of Parkinson’s disease in Italy from 1980 to 2015. Ulivelli M, Bezzini D, Kundisova L, Grazi I, Battaglia MA, Nante N, Rossi S.
Neurol Sci. 2022 Jan 30. doi: 10.1007/s10072-021-05854-3. Online ahead of print.
PMID: 35094172
6.
Abnormal multisensory integration in relapsing-remitting multiple sclerosis. Giurgola S, Casati C, Stampatori C, Perucca L, Mattioli F, Vallar G, Bolognini N.
Exp Brain Res. 2022 Jan 30. doi: 10.1007/s00221-022-06310-0. Online ahead of print.
PMID: 35094114
7.
A Deep Learning Approach to Predicting Disease Progression in Multiple Sclerosis Using Magnetic Resonance Imaging. Storelli L, Azzimonti M, Gueye M, Vizzino C, Preziosa P, Tedeschi G, De Stefano N, Pantano P, Filippi M, Rocca MA.
Invest Radiol. 2022 Jan 28. doi: 10.1097/RLI.0000000000000854. Online ahead of print.
PMID: 35093968
8.
Emotional processing intervention (EMOPRINT): A blinded randomized control trial to treat facial affect recognition deficits in multiple sclerosis. Genova HM, Lancaster K, Myszko Z, Morecraft J, Leddy J, Smith A, Chiaravalloti N, Lengenfelder J.
Mult Scler Relat Disord. 2022 Jan 19;59:103536. doi: 10.1016/j.msard.2022.103536. Online ahead of print.
PMID: 35093842
9.
Low vitamin D levels do not predict risk of autoimmune disease following alemtuzumab treatment for multiple sclerosis. Arnett S, Sanchez SJ, Downing J, Boggild M, Sun J, Broadley SA.
Mult Scler Relat Disord. 2022 Jan 10;59:103511. doi: 10.1016/j.msard.2022.103511. Online ahead of print.
PMID: 35093841
10.
Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications – A pilot study. Moser T, Otto F, O’Sullivan C, Hitzl W, Pilz G, Harrer A, Trinka E, Wipfler P.
Mult Scler Relat Disord. 2022 Jan 24;59:103560. doi: 10.1016/j.msard.2022.103560. Online ahead of print.
PMID: 35093840
11.
Contribution of relapse-associated worsening to overall disability accrual in patients with relapsing-onset multiple sclerosis: A mediation analysis. Chen B, Ji SQ, Shen F, Tian DS, Bu BT.
Mult Scler Relat Disord. 2022 Jan 22;59:103555. doi: 10.1016/j.msard.2022.103555. Online ahead of print.
PMID: 35093839
12.
Global DNA methylation changes in treated and untreated MS patients measured over time. Brorson IS, Eriksson AM, Høgestøl E, Leikfoss IS, Harbo HF, Berge T, Vitelli V, Bos SD.
J Neuroimmunol. 2022 Jan 7;364:577808. doi: 10.1016/j.jneuroim.2022.577808. Online ahead of print.
PMID: 35093762
13.
2-Chlorodeoxyadenosine (Cladribine) preferentially inhibits the biological activity of microglial cells. Aybar F, Julia Perez M, Silvina Marcora M, Eugenia Samman M, Marrodan M, María Pasquini J, Correale J.
Int Immunopharmacol. 2022 Jan 27;105:108571. doi: 10.1016/j.intimp.2022.108571. Online ahead of print.
PMID: 35093689
14.
Metabolomics and lipidomics approaches in human tears: A systematic review. Khanna RK, Catanese S, Emond P, Corcia P, Blasco H, Pisella PJ.
Surv Ophthalmol. 2022 Jan 27:S0039-6257(22)00008-X. doi: 10.1016/j.survophthal.2022.01.010. Online ahead of print.
PMID: 35093405 Review.
15.
Healthcare disruptions and use of telehealth services among persons with multiple sclerosis during the COVID-19 pandemic. Chen MH, Goverover Y, Botticello A, DeLuca J, Genova HM.
Arch Phys Med Rehabil. 2022 Jan 27:S0003-9993(22)00161-7. doi: 10.1016/j.apmr.2021.12.028. Online ahead of print.
PMID: 35093328
16.
Epigenomic priming of immune genes implicates oligodendroglia in multiple sclerosis susceptibility. Meijer M, Agirre E, Kabbe M, van Tuijn CA, Heskol A, Zheng C, Mendanha Falcão A, Bartosovic M, Kirby L, Calini D, Johnson MR, Corces MR, Montine TJ, Chen X, Chang HY, Malhotra D, Castelo-Branco G.
Neuron. 2022 Jan 28:S0896-6273(21)01089-8. doi: 10.1016/j.neuron.2021.12.034. Online ahead of print.
PMID: 35093191
17.
The common incidence-age multistep model of neurodegenerative diseases revisited: wider general age range of incidence corresponds to fewer disease steps. Gerovska D, Araúzo-Bravo MJ.
Cell Biosci. 2022 Jan 29;12(1):11. doi: 10.1186/s13578-021-00737-8.
PMID: 35093175
18.
Human olfactory mesenchymal stromal cell transplantation ameliorates experimental autoimmune encephalomyelitis revealing an inhibitory role for IL16 on myelination. Lindsay SL, Molęda AM, MacLellan LM, Keh SM, McElroy DE, Linington C, Goodyear CS, Barnett SC.
Acta Neuropathol Commun. 2022 Jan 29;10(1):12. doi: 10.1186/s40478-022-01316-9.
PMID: 35093166
19.
The effectiveness of decision aids for pregnancy related decision-making in women with pre-pregnancy morbidity; systematic review and meta-analysis. Whybrow R, Webster LM, Seed PT, Sandall J, Chappell LC.
BMC Pregnancy Childbirth. 2022 Jan 29;22(1):81. doi: 10.1186/s12884-022-04402-x.
PMID: 35093017
1.
Thermal dysregulation in patients with multiple sclerosis during SARS-CoV-2 infection. The potential therapeutic role of exercise. Razi O, Tartibian B, Teixeira AM, Zamani N, Govindasamy K, Suzuki K, Laher I, Zouhal H.
Mult Scler Relat Disord. 2022 Jan 24;59:103557. doi: 10.1016/j.msard.2022.103557. Online ahead of print.
PMID: 35092946 Review.
2.
Trends in administrative prevalence of multiple sclerosis and utilization patterns of disease modifying drugs in Germany. Holstiege J, Akmatov MK, Klimke K, Dammertz L, Kohring C, Marx C, Frahm N, Peters M, Ellenberger D, Zettl UK, Rommer PS, Stahmann A, Bätzing J.
Mult Scler Relat Disord. 2022 Jan 22;59:103534. doi: 10.1016/j.msard.2022.103534. Online ahead of print.
PMID: 35092945
3.
An exploratory study regarding communication facilitators and barriers reported by a cohort of multiple sclerosis (MS) community members from the international massive open online course ‘Understanding MS’. Campbell JA, Shaw SN, Mainsbridge C, Taylor BV, Claflin SB.
Mult Scler Relat Disord. 2021 Dec 23;59:103473. doi: 10.1016/j.msard.2021.103473. Online ahead of print.
PMID: 35092944
4.
Kappa free light chains: diagnostic performance in multiple sclerosis and utility in a clinical laboratory. Alves Martins D, Lopes J, Martins da Silva A, Iracema Morais C, Vasconcelos J, Lima I, Carneiro C, Neves E.
Clin Chim Acta. 2022 Jan 26:S0009-8981(22)00026-2. doi: 10.1016/j.cca.2022.01.017. Online ahead of print.
PMID: 35092724
5.
Association between relapses, stress, and depression in people with multiple sclerosis during the COVID-19 pandemic. Sparaco M, Miele G, Lavorgna L, Abbadessa G, Bonavita S.
Neurol Sci. 2022 Jan 29. doi: 10.1007/s10072-022-05917-z. Online ahead of print.
PMID: 35092543
6.
Multiple sclerosis and inflammatory bowel disease: A systematic review and meta-analysis. Wang X, Wan J, Wang M, Zhang Y, Wu K, Yang F.
Ann Clin Transl Neurol. 2022 Jan 29. doi: 10.1002/acn3.51495. Online ahead of print.
PMID: 35092169
7.
Subsecond accurate myelin water fraction reconstruction from FAST-T2 data with 3D UNET. Kim J, Nguyen TD, Zhang J, Gauthier SA, Marcille M, Zhang H, Cho J, Spincemaille P, Wang Y.
Magn Reson Med. 2022 Jan 28. doi: 10.1002/mrm.29176. Online ahead of print.
PMID: 35092094
8.
Single nucleotide variants around the connective tissue growth factor (CTGF/CCN2) gene and their association with multiple sclerosis risk, disability scores, and rate of disease progression. Can Demirdöğen B, Kılıç OO, Karagülle EN, Kalmaz LM, Mungan S.
Neurol Sci. 2022 Jan 29. doi: 10.1007/s10072-021-05852-5. Online ahead of print.
PMID: 35091888
9.
Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis. Rissanen E, Carter K, Cicero S, Ficke J, Kijewski M, Park MA, Kijewski J, Stern E, Chitnis T, Silbersweig D, Weiner HL, Kim CK, Lyons J, Klein JP, Bhattacharyya S, Singhal T.
Neurol Neuroimmunol Neuroinflamm. 2022 Jan 28;9(2):e1136. doi: 10.1212/NXI.0000000000001136. Print 2022 Mar.
PMID: 35091466
10.
Optic Nerve Lesion Length at the Acute Phase of Optic Neuritis Is Predictive of Retinal Neuronal Loss. Denis M, Woillez JP, Smirnov VM, Drumez E, Lannoy J, Boucher J, Zedet M, Pruvo JP, Labreuche J, Zephir H, Leclerc X, Outteryck O.
Neurol Neuroimmunol Neuroinflamm. 2022 Jan 28;9(2):e1135. doi: 10.1212/NXI.0000000000001135. Print 2022 Mar.
PMID: 35091465
11.
COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose. Dreyer-Alster S, Menascu S, Mandel M, Shirbint E, Magalashvili D, Dolev M, Flechter S, Givon U, Guber D, Stern Y, Miron S, Polliack M, Falb R, Sonis P, Gurevich M, Achiron A.
J Neurol Sci. 2022 Jan 21;434:120155. doi: 10.1016/j.jns.2022.120155. Online ahead of print.
PMID: 35091386
12.
Pregnancy outcomes following maternal or paternal exposure to teriflunomide in the Danish MS population. Andersen JB, Wandall-Holm MF, Magyari M.
Mult Scler Relat Disord. 2022 Jan 22;59:103529. doi: 10.1016/j.msard.2022.103529. Online ahead of print.
PMID: 35091367
13.
In multiple sclerosis, a Functional Independence Measure ≥ 107 is the best predictor of outcome after clean intermittent catheterization training. Haddad R, Lagnau P, Chesnel C, Miget G, Grasland M, Breton FL, Amarenco G, Hentzen C.
Ann Phys Rehabil Med. 2022 Jan 25:101636. doi: 10.1016/j.rehab.2022.101636. Online ahead of print.
PMID: 35091114
14.
Abnormal Oxidative Metabolism in the Cuprizone Mouse Model of Demyelination: an in vivo NIRS-MRI Study. Hashem M, Shafqat Q, Wu Y, Rho JM, Dunn JF.
Neuroimage. 2022 Jan 25:118935. doi: 10.1016/j.neuroimage.2022.118935. Online ahead of print.
PMID: 35091079
15.
Pterostilbene protects the optic nerves and retina in a murine model of experimental autoimmune encephalomyelitis via activation of SIRT1 signaling. Guo J, Wang J, Guo R, Shao H, Guo L.
Neuroscience. 2022 Jan 25:S0306-4522(22)00030-6. doi: 10.1016/j.neuroscience.2022.01.016. Online ahead of print.
PMID: 35090883
16.
Brain macrophages acquire distinct transcriptomes in multiple sclerosis lesions and normal appearing white matter. Miedema A, Gerrits E, Brouwer N, Jiang Q, Kracht L, Meijer M, Nutma E, Peferoen-Baert R, Pijnacker ATE, Wesseling EM, Wijering MHC, Gabius HJ, Amor S, Eggen BJL, Kooistra SM.
Acta Neuropathol Commun. 2022 Jan 28;10(1):8. doi: 10.1186/s40478-021-01306-3.
PMID: 35090578
17.
It is not a big deal: a qualitative study of clinical biobank donation experience and motives. Antonova N, Eritsyan K.
BMC Med Ethics. 2022 Jan 29;23(1):7. doi: 10.1186/s12910-022-00743-6.
PMID: 35090454
18.
Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis. Rezaee M, Morowvat MH, Poursadeghfard M, Radgoudarzi A, Keshavarz K.
BMC Health Serv Res. 2022 Jan 28;22(1):118. doi: 10.1186/s12913-022-07495-4.
PMID: 35090438
1.
Engineered extracellular vesicles encapsulated Bryostatin-1 as therapy for neuroinflammation. Wu WC, Tian J, Xiao D, Guo YX, Xiao Y, Wu XY, Casella G, Rasouli J, Yan YP, Rostami A, Wang LB, Zhang Y, Li X.
Nanoscale. 2022 Jan 28. doi: 10.1039/d1nr05517h. Online ahead of print.
PMID: 35088795
2.
The Fast Gray Matter Acquisition T1 Inversion Recovery Sequence in Deep Brain Stimulation: Introducing the Rubral Wing for Dentato-Rubro-Thalamic Tract Depiction and Tremor Control. Bot M, Pauwels R, van den Munckhof P, de Win M, Odekerken VJJ, Beudel M, Dijk J, de Bie RMA, Schuurman PR.
Neuromodulation. 2022 Jan 15:S1094-7159(21)06948-8. doi: 10.1016/j.neurom.2021.11.015. Online ahead of print.
PMID: 35088745
3.
A case of multiple sclerosis with protracted course of COVID-19. Hasibi M, Asadollahi M, Asadollahi-Amin A.
Infect Disord Drug Targets. 2022 Jan 28. doi: 10.2174/1871526522666220128121855. Online ahead of print.
PMID: 35088680
4.
Trends in the use of disease-modifying therapies among reproductive-aged women with multiple sclerosis in the United States from 2010-2019. Duchesneau ED, Kinlaw AC, Jonsson Funk M, Pate V, Lund JL.
Pharmacoepidemiol Drug Saf. 2022 Jan 27. doi: 10.1002/pds.5411. Online ahead of print.
PMID: 35088492
5.
Bridging the callosal gap in gait: corpus callosum white matter integrity’s role in lower limb coordination. Richmond SB, Peterson DS, Fling BW.
Brain Imaging Behav. 2022 Jan 28. doi: 10.1007/s11682-021-00612-7. Online ahead of print.
PMID: 35088352
6.
Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis. Virgilio E, Vecchio D, Crespi I, Puricelli C, Barbero P, Galli G, Cantello R, Dianzani U, Comi C.
J Neurol. 2022 Jan 28. doi: 10.1007/s00415-021-10945-4. Online ahead of print.
PMID: 35088141
7.
Changes in trunk and head acceleration during the 6-minute walk test and its relation to falls risk for adults with multiple sclerosis. Morrison S, Armitano-Lago C, Rynders CA, Sosnoff JJ.
Exp Brain Res. 2022 Jan 28. doi: 10.1007/s00221-021-06296-1. Online ahead of print.
PMID: 35088117
8.
Identification of the genetic mechanism that associates L3MBTL3 to multiple sclerosis. Alcina A, Fedetz M, Vidal-Cobo I, Andrés-León E, García-Sánchez MI, Barroso-Del-Jesus A, Eichau S, Gil-Varea E, Villar LM, Saiz A, Leyva L, Vandenbroeck K, Otaegui D, Izquierdo G, Comabella M, Urcelay E, Matesanz F.
Hum Mol Genet. 2022 Jan 28:ddac009. doi: 10.1093/hmg/ddac009. Online ahead of print.
PMID: 35088080
9.
Study of soldiers implicates common virus as MS trigger. Kaiser J.
Science. 2022 Jan 14;375(6577):133. doi: 10.1126/science.ada0059. Epub 2022 Jan 13.
PMID: 35025651
10.
Autoimmune Encephalitis and Autoantibodies: A Review of Clinical Implications. Hébert J, Muccilli A, Wennberg RA, Tang-Wai DF.
J Appl Lab Med. 2022 Jan 5;7(1):81-98. doi: 10.1093/jalm/jfab102.
PMID: 34996085 Review.
11.
Paraneoplastic myelopathy with amphiphysin autoantibodies and lobular breast carcinoma in situ. Alexandres CA, Tremblay MA, Klassen CL, Degnim A, Flanagan EP.
J Neurol Sci. 2022 Jan 15;432:120086. doi: 10.1016/j.jns.2021.120086. Epub 2021 Dec 11.
PMID: 34920159 No abstract available.
12.
Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population. Papathanasiou A, Tanasescu R, Tench CR, Rocha MF, Bose S, Constantinescu CS, Jacob S.
J Neurol Sci. 2021 Dec 15;431:120039. doi: 10.1016/j.jns.2021.120039. Epub 2021 Oct 24.
PMID: 34715481
13.
Cell-based drug delivery harnesses inflammatory and autoimmune responses in neurodegeneration. Pozo D.
J Mol Med (Berl). 2021 May;99(5):673-674. doi: 10.1007/s00109-021-02059-1. Epub 2021 Mar 8.
PMID: 33683375 Free PMC article. No abstract available.
14.
DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia. Hannon E, Dempster EL, Mansell G, Burrage J, Bass N, Bohlken MM, Corvin A, Curtis CJ, Dempster consortium, Sullivan P, Vassos E, Breen G, Collier DA, Murray RM, Schalkwyk LS, Mill J.
Elife. 2021 Feb 26;10:e58430. doi: 10.7554/eLife.58430.
PMID: 33646943 Free PMC article.
1.
Vision Prognosis and Associated Factors of Optic Neuritis in Dependence of Glial Autoimmune Antibodies. Yang M, Wu Y, Song H, Lai M, Li H, Sun M, Zhao J, Fu J, Xu X, Xie L, Wang Y, Zhou H, Xu Q, Wu W, Jonas JB, Wei S.
Am J Ophthalmol. 2022 Jan 23:S0002-9394(22)00016-2. doi: 10.1016/j.ajo.2022.01.015. Online ahead of print.
PMID: 35081416
2.
Oligodendrocytes and Myelin: Active players in Neurodegenerative brains? Chen JF, Wang F, Huang NX, Xiao L, Mei F.
Dev Neurobiol. 2022 Jan 26. doi: 10.1002/dneu.22867. Online ahead of print.
PMID: 35081276 Review.
3.
Citrullination in the pathology of inflammatory and autoimmune disorders: recent advances and future perspectives. Ciesielski O, Biesiekierska M, Panthu B, Soszyński M, Pirola L, Balcerczyk A.
Cell Mol Life Sci. 2022 Jan 25;79(2):94. doi: 10.1007/s00018-022-04126-3.
PMID: 35079870 Review.
4.
Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: A case report. Rauniyar R, Rauniyar R, Agrawal A, Yadav S, Avula S.
Clin Case Rep. 2022 Jan 19;10(1):e05299. doi: 10.1002/ccr3.5299. eCollection 2022 Jan.
PMID: 35079395 Free PMC article.
5.
Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocol. Golla H, Dillen K, Hellmich M, Dojan T, Ungeheuer S, Schmalz P, Staß A, Mildenberger V, Goereci Y, Dunkl V, Strupp J, Fink GR, Voltz R, Stock S, Cornely O, Stahmann A, Müller A, Löcherbach P, Burghaus L, Limmroth V, Bonmann E, Gerbershagen K, Nelles G, Joist T, Haas J, Temmes H, Warnke C.
BMJ Open. 2022 Jan 25;12(1):e049300. doi: 10.1136/bmjopen-2021-049300.
PMID: 35078833
6.
Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration. Verma M, Lizama BN, Chu CT.
Transl Neurodegener. 2022 Jan 25;11(1):3. doi: 10.1186/s40035-021-00278-7.
PMID: 35078537 Review.
7.
Thoracic lymphadenopathies in diffuse systemic sclerosis: an observational study on 48 patients using computed tomography. Renaud A, Pautre R, Morla O, Achille A, Durant C, Espitia O, Frampas E, Agard C.
BMC Pulm Med. 2022 Jan 25;22(1):44. doi: 10.1186/s12890-022-01837-y.
PMID: 35078448
8.
Additive and interaction effects of working memory and motor sequence training on brain functional connectivity. Zuber P, Gaetano L, Griffa A, Huerbin M, Pedullà L, Bonzano L, Altermatt A, Tsagkas C, Parmar K, Hagmann P, Wuerfel J, Kappos L, Sprenger T, Sporns O, Magon S.
Sci Rep. 2021 Nov 29;11(1):23089. doi: 10.1038/s41598-021-02492-9.
PMID: 34845312 Free PMC article.
9.
Unraveling the Role of Dopaminergic and Calretinin Interneurons in the Olfactory Bulb. Capsoni S, Fogli Iseppe A, Casciano F, Pignatelli A.
Front Neural Circuits. 2021 Oct 8;15:718221. doi: 10.3389/fncir.2021.718221. eCollection 2021.
PMID: 34690707 Free PMC article. Review.
10.
Sarcoidosis and neuromyelitis optica in a patient with optic neuritis – a case report. Foster MA, Collorone S, Palace J, Acheson J, Toosy AT.
Ann Clin Transl Neurol. 2021 Aug;8(8):1760-1763. doi: 10.1002/acn3.51413. Epub 2021 Jun 24.
PMID: 34166585 Free PMC article.
11.
Itaconate confers tolerance to late NLRP3 inflammasome activation. Bambouskova M, Potuckova L, Paulenda T, Kerndl M, Mogilenko DA, Lizotte K, Swain A, Hayes S, Sheldon RD, Kim H, Kapadnis U, Ellis AE, Isaguirre C, Burdess S, Laha A, Amarasinghe GK, Chubukov V, Roddy TP, Diamond MS, Jones RG, Simons DM, Artyomov MN.
Cell Rep. 2021 Mar 9;34(10):108756. doi: 10.1016/j.celrep.2021.108756.
PMID: 33691097 Free PMC article.
1.
To the editors: Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England. Tugemann B, Manouchehri N, Stuve O.
Mult Scler Relat Disord. 2022 Jan 19;59:103541. doi: 10.1016/j.msard.2022.103541. Online ahead of print.
PMID: 35078128 No abstract available.
2.
Two-dimensional measurements with cut-off values are useful for assessing brain volume, physical disability, and processing speed in multiple sclerosis. Nishizawa K, Fujimori J, Nakashima I.
Mult Scler Relat Disord. 2022 Jan 20;59:103543. doi: 10.1016/j.msard.2022.103543. Online ahead of print.
PMID: 35078126
3.
High or increasing serum NfL is predictive of impending multiple sclerosis relapses. Thebault S, Reaume M, Marrie RA, Marriott JJ, Furlan R, Laroni A, Booth RA, Uccelli A, Freedman MS.
Mult Scler Relat Disord. 2022 Jan 19;59:103535. doi: 10.1016/j.msard.2022.103535. Online ahead of print.
PMID: 35078125
4.
Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis. Park SJ, Yeon SK, Kim Y, Kim HJ, Kim S, Kim J, Choi JW, Kim B, Lee EH, Kim R, Seo SH, Lee J, Kim JW, Lee HY, Hwang H, Bahn YS, Cheong E, Park JH, Park KD.
J Med Chem. 2022 Jan 25. doi: 10.1021/acs.jmedchem.1c01979. Online ahead of print.
PMID: 35077170
5.
Correction to: Reliability of televisits for patients with mild relapsing-remitting multiple sclerosis in the COVID‑19 era. Toscano S, Patti F, Chisari CG, Arena S, Finocchiaro C, Schillaci CE, Zappia M.
Neurol Sci. 2022 Jan 25. doi: 10.1007/s10072-022-05905-3. Online ahead of print.
PMID: 35076808 No abstract available.
6.
Modulation of Pacemaker Channel Function in a Model of Thalamocortical Hyperexcitability by Demyelination and Cytokines. Chaudhary R, Albrecht S, Datunashvili M, Cerina M, Lüttjohann A, Han Y, Narayanan V, Chetkovich DM, Ruck T, Kuhlmann T, Pape HC, Meuth SG, Zobeiri M, Budde T.
Cereb Cortex. 2022 Jan 25:bhab491. doi: 10.1093/cercor/bhab491. Online ahead of print.
PMID: 35076711
7.
Teriflunomide Reduced Lesions in Pediatric Multiple Sclerosis. Slomski A.
JAMA. 2022 Jan 25;327(4):314. doi: 10.1001/jama.2021.25109.
PMID: 35076668 No abstract available.
8.
Epidemiological investigation of multiple sclerosis and related medical utilisation in Taiwan. Liao CM, Kuo WY, Kung PT, Chuan CH, Tsai WC.
Mult Scler. 2022 Jan 25:13524585211061341. doi: 10.1177/13524585211061341. Online ahead of print.
PMID: 35076314
9.
Impact of COVID-19 lockdown on progressive multiple sclerosis patients. Vercellino M, Bosa C, Alteno A, Schillaci V, Petracca M, Marasciulo S, Cavalla P.
Neurol Sci. 2022 Jan 24. doi: 10.1007/s10072-022-05909-z. Online ahead of print.
PMID: 35075574
10.
Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Chia R, Saez-Atienzar S, Murphy N, Chiò A, Blauwendraat C; International Myasthenia Gravis Genomics Consortium, Roda RH, Tienari PJ, Kaminski HJ, Ricciardi R, Guida M, De Rosa A, Petrucci L, Evoli A, Provenzano C, Drachman DB, Traynor BJ.
Proc Natl Acad Sci U S A. 2022 Feb 1;119(5):e2108672119. doi: 10.1073/pnas.2108672119.
PMID: 35074870
11.
Recurrent intracranial hemorrhage in a patient with relapsing multiple sclerosis under interferon-β therapy. Sánchez-Soblechero A, Cuello JP, Martínez Ginés ML, Lozano Ros A, Romero Delgado F, De Andrés C, Goicochea Briceño H, García Domínguez JM.
Neurologia (Engl Ed). 2022 Jan-Feb;37(1):77-79. doi: 10.1016/j.nrleng.2021.02.007.
PMID: 35074194 No abstract available.
12.
Advantages of using the optic nerve ecography to predict clinical progression in multiple sclerosis. Guzman I, Gomez R.
Neurologia (Engl Ed). 2022 Jan-Feb;37(1):73. doi: 10.1016/j.nrleng.2021.07.001.
PMID: 35074191 No abstract available.
13.
Movement disorders. Ganz JC.
Prog Brain Res. 2022;268(1):379-384. doi: 10.1016/bs.pbr.2021.10.042. Epub 2021 Dec 14.
PMID: 35074091
14.
Trigeminal neuralgia and other cranial pain syndromes. Ganz JC.
Prog Brain Res. 2022;268(1):347-378. doi: 10.1016/bs.pbr.2021.10.041. Epub 2022 Jan 13.
PMID: 35074090
15.
Clinical utility of the Trendelenburg Test in people with multiple sclerosis. Kline PW, Christiansen CL, Judd DL, Mañago MM.
Physiother Theory Pract. 2022 Jan 24:1-8. doi: 10.1080/09593985.2022.2030446. Online ahead of print.
PMID: 35073816
16.
Successful Use of Infliximab for Refractory Genital Ulceration in a Patient With Multiple Sclerosis and Behçet Disease. Bayard MF, Bunker D, Katz Sand IB, Fenske SS, Sultan K, Ali Y.
J Clin Rheumatol. 2021 Dec 1;27(8S):S880-S882. doi: 10.1097/RHU.0000000000000659.
PMID: 35073644 No abstract available.
1.
Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM. Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, Fernandes RA, Gomez AM, Nadj GS, Bartley CM, Schubert RD, Hawes IA, Vazquez SE, Iyer M, Zuchero JB, Teegen B, Dunn JE, Lock CB, Kipp LB, Cotham VC, Ueberheide BM, Aftab BT, Anderson MS, DeRisi JL, Wilson MR, Bashford-Rogers RJM, Platten M, Garcia KC, Steinman L, Robinson WH.
Nature. 2022 Jan 24. doi: 10.1038/s41586-022-04432-7. Online ahead of print.
PMID: 35073561
2.
Impact of CYBA genotypes on severity and progression of multiple sclerosis. Törnell A, Kiffin R, Haghighi S, Mossberg N, Andersen O, Hellstrand K, Martner A.
Eur J Neurol. 2022 Jan 24. doi: 10.1111/ene.15259. Online ahead of print.
PMID: 35073438
3.
Remote Patient Monitoring for Neuropsychiatric Disorders: A Scoping Review of Current Trends and Future Perspectives from Recent Publications and Upcoming Clinical Trials. Sakamaki T, Furusawa Y, Hayashi A, Otsuka M, Fernandez J.
Telemed J E Health. 2022 Jan 24. doi: 10.1089/tmj.2021.0489. Online ahead of print.
PMID: 35073206
4.
Therapeutic Potential of Combined Therapy of Vitamin A and Vitamin C in the Experimental Autoimmune Encephalomyelitis (EAE) in Lewis Rats. Navidhamidi M, Nazari A, Dehghan S, Ebrahimpour A, Nasrnezhad R, Pourabdolhossein F.
Mol Neurobiol. 2022 Jan 24. doi: 10.1007/s12035-022-02755-0. Online ahead of print.
PMID: 35072933
5.
Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy. Hellwig K, Tokic M, Thiel S, Esters N, Spicher C, Timmesfeld N, Ciplea AI, Gold R, Langer-Gould A.
JAMA Netw Open. 2022 Jan 4;5(1):e2144750. doi: 10.1001/jamanetworkopen.2021.44750.
PMID: 35072719
6.
Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination. König M, Torgauten HM, Tran TT, Holmøy T, Vaage JT, Lund-Johansen F, Nygaard GO.
JAMA Neurol. 2022 Jan 24. doi: 10.1001/jamaneurol.2021.5109. Online ahead of print.
PMID: 35072702 No abstract available.
7.
Protocol for the assessment of human T cell activation by real-time metabolic flux analysis. Kong BS, Lee C, Cho YM.
STAR Protoc. 2022 Jan 11;3(1):101084. doi: 10.1016/j.xpro.2021.101084. eCollection 2022 Mar 18.
PMID: 35072113 Free PMC article.
8.
Using real-world accelerometry-derived diurnal patterns of physical activity to evaluate disability in multiple sclerosis. Keller JL, Tian F, Fitzgerald KC, Mische L, Ritter J, Costello MG, Mowry EM, Zippunikov V, Zackowski KM.
J Rehabil Assist Technol Eng. 2022 Jan 12;9:20556683211067362. doi: 10.1177/20556683211067362. eCollection 2022 Jan-Dec.
PMID: 35070348 Free PMC article. No abstract available.
9.
The need for a strategic therapeutic approach: multiple sclerosis in check. Inojosa H, Proschmann U, Akgün K, Ziemssen T.
Ther Adv Chronic Dis. 2022 Jan 18;13:20406223211063032. doi: 10.1177/20406223211063032. eCollection 2022.
PMID: 35070250 Free PMC article. Review.
10.
Mechanistic and Biomarker Studies to Demonstrate Immune Tolerance in Multiple Sclerosis. Docampo MJ, Lutterotti A, Sospedra M, Martin R.
Front Immunol. 2022 Jan 5;12:787498. doi: 10.3389/fimmu.2021.787498. eCollection 2021.
PMID: 35069562 Free PMC article. Review.
11.
Worse Physical Disability Is Associated With the Expression of PD-1 on Inflammatory T-Cells in Multiple Sclerosis Patients With Older Appearing Brains. Jacobs SAH, Muraro PA, Cencioni MT, Knowles S, Cole JH, Nicholas R.
Front Neurol. 2022 Jan 6;12:801097. doi: 10.3389/fneur.2021.801097. eCollection 2021.
PMID: 35069428 Free PMC article.
12.
Systematic Review of the Socioeconomic Consequences in Patients With Multiple Sclerosis With Different Levels of Disability and Cognitive Function. Kavaliunas A, Danylaitė Karrenbauer V, Binzer S, Hillert J.
Front Neurol. 2022 Jan 6;12:737211. doi: 10.3389/fneur.2021.737211. eCollection 2021.
PMID: 35069404 Free PMC article.
13.
Do dietary interventions improve health outcomes in people with multiple sclerosis? A cochrane review summary with commentary. Amatya B, Khan F.
NeuroRehabilitation. 2022 Jan 19. doi: 10.3233/NRE-228000. Online ahead of print.
PMID: 35068420
14.
Transcriptional effects of fingolimod treatment on peripheral T cells in relapsing remitting multiple sclerosis patients. Sferruzza G, Clarelli F, Mascia E, Ferrè L, Ottoboni L, Sorosina M, Santoro S, Filippi M, Provero P, Esposito F.
Pharmacogenomics. 2022 Jan 24. doi: 10.2217/pgs-2021-0118. Online ahead of print.
PMID: 35068175
Napsat komentář
Pro přidávání komentářů se musíte nejdříve přihlásit.